Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: The effect of the European Cooperative Acute Stroke Study (ECASS) III trial

Felipe De Los Ríos La Rosa, Jane Khoury, Brett M. Kissela, Matthew L. Flaherty, Kathleen Alwell, Charles J. Moomaw, Pooja Khatri, Opeolu Adeoye, Daniel Woo, Simona Ferioli, Dawn O. Kleindorfer

Research output: Contribution to journalArticlepeer-review

124 Scopus citations

Abstract

Background and Purpose-: The publication of the European Cooperative Acute Stroke Study (ECASS III) expanded the treatment time to thrombolysis for acute ischemic stroke from 3 to 4.5 hours from symptom onset. The impact of the expanded time window on treatment rates has not been comprehensively evaluated in a population-based study. Methods-: All patients with an ischemic stroke presenting to an emergency department during calendar year 2005 in the 17 hospitals that compromise the large 1.3 million Greater Cincinnati/Northern Kentucky population were included in the analysis. Criteria for exclusion from thrombolytic therapy are analyzed retrospectively for both the standard and expanded timeframes with varying door-to-needle times. Results-: During the study period, 1838 ischemic strokes presenting to an emergency department were identified. A small proportion of them arrived in the expanded time window (3.4%) compared with the standard time window (22%). Only 0.5% of those who arrived in this timeframe met eligibility criteria for thrombolysis compared with 5.9% using standard eligibility criteria in the standard timeframe. These Results did not vary significantly by repeated analysis varying the door-to-needle time or the expanded time window's exclusion criteria. Conclusions-: In reality, the expanded time window for thrombolysis in acute ischemic stroke benefits few patients. If we are to improve recombinant tissue-type plasminogen activator administration rates, our focus should be on improving stroke awareness, transport to facilities with ability to administer thrombolysis, and familiarity of physicians with acute stroke treatment guidelines.

Original languageEnglish
Pages (from-to)1591-1595
Number of pages5
JournalStroke
Volume43
Issue number6
DOIs
StatePublished - Jun 2012

Keywords

  • acute stroke
  • ECASS
  • epidemiology
  • stroke care
  • thrombolysis

Fingerprint

Dive into the research topics of 'Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: The effect of the European Cooperative Acute Stroke Study (ECASS) III trial'. Together they form a unique fingerprint.

Cite this